Thiothixene, marketed in the US as Navane, belongs to a smaller, less famous family of antipsychotics called the thioxanthenes. The thioxanthenes (chlorprothixene, thiothixene, zuclopenthixol, flupentixol) share a chemical backbone with the phenothiazines but with a key difference: a carbon atom replaces the nitrogen at the 10 position. Pharmacologically, thiothixene behaves much like a high-potency phenothiazine such as fluphenazine — strong dopamine D2 blockade, less anticholinergic and antihistamine burden than chlorpromazine, more risk of acute extrapyramidal symptoms.
Thiothixene is a high-potency first-generation antipsychotic for schizophrenia, with prominent D2 blockade, lower sedation than low-potency agents, and a relatively high rate of movement side effects.
How it works
Thiothixene primarily blocks dopamine D2 receptors. It has lower affinity than chlorpromazine for histamine H1 and muscarinic receptors, so sedation, dry mouth, and constipation tend to be less prominent. Alpha-1 blockade and orthostatic hypotension are less marked than with low-potency phenothiazines. The trade-off is a higher rate of acute EPS — dystonia, parkinsonism, akathisia.
FDA-approved indication
According to the DailyMed thiothixene label, the indication is the management of schizophrenia in adults. It is not recommended for behavioural problems in children or for dementia-related psychosis.
Typical dosing
The FDA label describes typical adult oral doses of 6 to 30 mg per day in divided doses for moderate to severe schizophrenia, with lower starting doses for milder presentations. Doses above 60 mg per day are generally not recommended because efficacy plateaus and side effect burden rises sharply. Older adults are started at much lower doses.
Side effects
Movement effects
Acute dystonia (involuntary muscle contractions, often of the neck or eyes), parkinsonism (tremor, stiffness, slowed movements), and akathisia (inner restlessness) are common in the first weeks of treatment, particularly at higher doses. Anticholinergic medications such as benztropine or trihexyphenidyl are sometimes co-prescribed. See our EPS overview and akathisia management guide.
Tardive dyskinesia
Long-term use of any first-generation antipsychotic carries a meaningful risk of tardive dyskinesia — involuntary movements that can persist after the drug is stopped. The risk increases with cumulative dose and time on treatment.
Sedation and metabolic effects
Sedation is generally mild to moderate. Weight gain and metabolic effects are less than with chlorpromazine, olanzapine, or clozapine, but periodic monitoring of weight, glucose, and lipids is reasonable.
Hyperprolactinemia
Like other D2 blockers, thiothixene raises prolactin and can cause sexual dysfunction, breast changes, and menstrual disturbance. See our prolactin guide.
Cardiovascular
QT prolongation can occur, particularly at higher doses or in combination with other QT-prolonging drugs. Orthostatic hypotension is less marked than with chlorpromazine but still occurs.
Other
Lowered seizure threshold, photosensitivity, and rare cholestatic effects can occur. Neuroleptic malignant syndrome — a rare but life-threatening reaction characterised by fever, rigidity, autonomic instability, and altered mental status — is a class effect of antipsychotics.
Severe muscle stiffness with high fever and confusion, sudden involuntary movements you cannot control, or signs of a serious allergic reaction.
Boxed warning
Like all antipsychotics, thiothixene carries the FDA boxed warning about increased mortality in elderly patients with dementia-related psychosis.
Drug interactions
Additive sedation with alcohol, benzodiazepines, and opioids. Additive QT effects with other QT-prolonging drugs. Anticholinergic effects can compound those of other anticholinergics. Always tell prescribers about all medications and supplements.
Where thiothixene fits in 2026
Modern guidelines, including NICE and the APA, generally recommend second-generation antipsychotics first. Thiothixene retains a role in:
- Patients who have done well historically on it and want to continue
- Settings where cost or formulary constraints limit access to newer agents
- Cases where a high-potency typical is preferred over haloperidol because of an individual response or tolerability pattern
- Patients who cannot tolerate the metabolic side effect burden of newer agents
The drug is rarely chosen as first-line for new patients today, both because of its EPS burden and because newer agents with better tolerability profiles are widely available.
Practical questions to ask your prescriber
- Why thiothixene rather than a newer agent?
- What is the plan for monitoring movement side effects (e.g., AIMS exam)?
- Should I have an anticholinergic on hand for acute dystonia?
- What baseline ECG, weight, and labs do I need?
The big picture
Thiothixene is one of the working veterans of psychopharmacology. It is not a flashy drug, it is rarely studied in modern trials, and it is not first-line in most settings. But for patients who have done well on it and tolerate it, it remains a legitimate option with decades of clinical experience behind it. The question of whether it fits — and whether to switch to a newer agent — is best worked out with a prescriber who knows your history.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling, regulatory sources, and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication.